Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

The Unfolded Protein Response Mediates Resistance in AML and Its Therapeutic Targeting Enhances TKI Induced Cell Death in FLT3-ITD + AML

Timo Jaquet, Christian Preisinger, Marlena Bütow, Stefan Tillmann, Nicolas Chatain, Michael Huber, Steffen Koschmieder, Martin Kirschner, Edgar Jost, Tim H Brümmendorf, Bezhad Kharabi, Iris Appelmann, Mirle Schemionek

Blood (2021) 138 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2021-150066

Published: 2021

Journal Articles

Interplay between PI3K/mTOR Signaling and IRE1a-XBP1 Promotes Survival of Pre-B NRAS G12D all Cells Providing a Therapeutic Vulnerability for the "Undruggable" Driver RAS

Iris Appelmann, MD, Azam Salimi, Michael Huber, PhD, Mirle Schemionek, PhD, Margherita Vieri, PhD, Tim H Brümmendorf, MD, John B. Patterson, Behzad Kharabi Masouleh, MD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-140299

Published: 2020

Journal Articles

The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy

Blood (2019) 133 (6): 550–565.

https://doi.org/10.1182/blood-2018-07-866830

Published: 2019

Includes: Supplemental data

Journal Articles

The HLA Ligandome Landscape of Chronic Myeloid Leukemia Delineates Novel T-Cell Epitopes for Immunotherapy

Blood (2018) 132 (Supplement 1): 4243.

https://doi.org/10.1182/blood-2018-99-113376

Published: 2018

Journal Articles

Eosinophil Differentiation and Viability in Hypereosinophilia Is Impaired By Genetic and Pharmacologic Targeting of LCP1 and PKC Beta

Guangxin Ma, Deniz Gezer, MD, Oliver Herrmann, Msc, Andreas Reiter, MD, Mohamad Jawhar, Mirle Schemionek, Tim H. Brümmendorf, MD, Steffen Koschmieder, MD, Nicolas Chatain, PhD

Blood (2018) 132 (Supplement 1): 4320.

https://doi.org/10.1182/blood-2018-99-114646

Published: 2018

Journal Articles

Synergistic Dual Inhibition of BCR-ABL1 and the Unfolded Protein Response Causes p38 MAPK-Mediated Cell Death and Sensitizes BCR-ABL1 + Acute Lymphoblastic Leukemia to Dexamethasone

Margherita Vieri, MSc, Christian Preisinger, Mirle Schemionek, Azam Salimi, John B. Patterson, Afshin Samali, Tim H Brümmendorf, MD, Iris Appelmann, MD, Behzad Kharabi Masouleh, MD

Blood (2018) 132 (Supplement 1): 4674.

https://doi.org/10.1182/blood-2018-99-110967

Published: 2018

Journal Articles

Critical Interferon-Response Genes Are Induced By JAK2 V617F but Repressed By BCR-ABL, and They Are Responsible for the Differential Effects of Interferon in PV Vs. CML

Claudia Schubert, Ivan G. Costa, Mirle Schemionek, PhD, Kristina Feldberg, Julian Baumeister, Tim H. Brümmendorf, MD, Steffen Koschmieder, Nicolas Chatain

Blood (2017) 130 (Supplement 1): 4226.

https://doi.org/10.1182/blood.V130.Suppl_1.4226.4226

Published: 2017

Journal Articles

Bcr-Abl1 Kinase-Independent Upregulation of FcγRIIb Mediates Malignant Signaling That Is Critical for Leukemogenesis

Oliver Herrmann, Msc, Samantha Langer, Caroline Wessling, Michael Huber, PhD, Shaoguang Li, MD PhD, Tim Henrik Bruemmendorf, Steffen Koschmieder, Mirle Schemionek, PhD

Blood (2017) 130 (Supplement 1): 2862.

https://doi.org/10.1182/blood.V130.Suppl_1.2862.2862

Published: 2017

Journal Articles

Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia Identifies Novel CD8 + and CD4 + T Cell-Epitopes for Immunotherapeutic Approaches

Tatjana Bilich, Annika Nelde, Daniel J. Kowalewski, Janet Peper, Mirle Schemionek, PhD, Lothar Kanz, MD, Helmut R. Salih, MD, Tim H. Brümmendorf, MD, Vladan Vucinic, MD, Dietger Niederwieser, MD, Hans-Georg Rammensee, PhD, Stefan Stevanovic, PhD, Juliane S. Stickel, MD

Blood (2016) 128 (22): 4232.

https://doi.org/10.1182/blood.V128.22.4232.4232

Published: 2016

Journal Articles

Telomere Length Shortening in the CML Leukemic Stem Cell Compartment Correlates with the Respective Clone Size: Evidence for Early Vs. Late Chronic Phase

Anne-Sophie Bouillon, Monica S. Ferreira, PhD, Shady Adnan Awad, Johan Richter, MD, Henrik Hjorth-Hansen, MD PhD, Thoas Fioretos, Sebastian Hummel, Mirle Schemionek, PhD, Satu Mustjoki, MD PhD, Fabian Beier, MD, Tim H. Brümmendorf, MD

Blood (2016) 128 (22): 4243.

https://doi.org/10.1182/blood.V128.22.4243.4243

Published: 2016

Journal Articles

Elucidation of Additional Mutations By Next-Generation Sequencing Is of Clinical Significance in Patients with Rare MPNs and MDS/MPN Overlap Syndromes

Martin MJ Kirschner, MD, Mirle Schemionek, PhD, Matthias Begemann, PhD, Susanne Isfort, MD, Kristina Feldberg, Tim H. Brümmendorf, MD, Steffen Koschmieder, MD

Blood (2016) 128 (22): 4260.

https://doi.org/10.1182/blood.V128.22.4260.4260

Published: 2016

Journal Articles

HLA Ligandome Analysis of Different Hematological Malignancies Identifies a Small Panel of "Pan-Leukemia"-Associated Antigens

Linus Backert, Daniel J. Kowalewski, Simon D. Walz, Heiko Schuster, Claudia Berlin, Mirle Schemionek, PhD, Tim H. Brümmendorf, MD, Vladan Vucinic, MD, Dietger Niederwieser, MD, Lothar Kanz, MD, Helmut R. Salih, MD, Katja Weisel, MD, Hans-Georg Rammensee, PhD, Stefan Stevanovic, PhD, Juliane S. Stickel, MD

Blood (2016) 128 (22): 2169.

https://doi.org/10.1182/blood.V128.22.2169.2169

Published: 2016

Journal Articles

Dasatinib Exerts Differential Effects on Normal and BCR-ABL Positive Hematopoietic Cells in a Transgenic Mouse Model of Chronic Phase-CML

Claudia Schubert, Msc, Nicolas Chatain, PhD, Till Braunschweig, MD, Mirle Schemionek, PhD, Kristina Feldberg, Melanie Hoffmann, Tim H. Brümmendorf, MD, Satu Mustjoki, MD PhD, Olli Dufva, Steffen Koschmieder, MD

Blood (2016) 128 (22): 1885.

https://doi.org/10.1182/blood.V128.22.1885.1885

Published: 2016

Journal Articles

A Novel TNF-Alpha Antibody Based Therapeutic Approach to Target Leukemic Stem Cells in Bcr-Abl Disease

Oliver Herrmann, Msc, Claudia Schubert, Msc, Tom Luedde, MD PhD, Till Braunschweig, MD, Steffen Koschmieder, MD, Tim H Brümmendorf, MD, Mirle Schemionek, PhD

Blood (2015) 126 (23): 15.

https://doi.org/10.1182/blood.V126.23.15.15

Published: 2015

Journal Articles

Genetic Depletion of Fc Gamma Receptor 2b Affects CML Stem Cell Biology

Oliver Herrmann, MSc, Caroline CA Weßling, MD, Michael Huber, PhD, Shaoguang Li, MD PhD, Tim H. Brümmendorf, MD, Steffen Koschmieder, MD, Mirle Schemionek, PhD

Blood (2014) 124 (21): 4528.

https://doi.org/10.1182/blood.V124.21.4528.4528

Published: 2014

Journal Articles

Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia (CML)—Towards Peptide Based Immunotherapy

Daniel J. Kowalewski, Mirle Schemionek, Lothar Kanz, MD, Helmut R. Salih, MD, Tim H. Brümmendorf, MD, Vladan Vucinic, MD, Dietger Niederwieser, MD, Hans-Georg Rammensee, PhD, Stefan Stevanovic, PhD, Juliane S. Stickel, MD

Blood (2014) 124 (21): 4518.

https://doi.org/10.1182/blood.V124.21.4518.4518

Published: 2014

Journal Articles

Dissecting Genomic Aberrations In CML and Bcr-Abl Negative Myeloproliferative Neoplasms By The Use Of Multiplex-PCR and Parallel Resequencing

Martin M. Kirschner, Mirle Schemionek, Claudia Schubert, Nicolas Chatain, Stephanie Sontag, Susanne Isfort, Nadina Ortiz-Brüchle, Karla Bennemann, Klaus Zerres, Martin Zenke, Tim H. Bruemmendorf, MD, Steffen Koschmieder

Blood (2013) 122 (21): 1612.

https://doi.org/10.1182/blood.V122.21.1612.1612

Published: 2013

Journal Articles

HLA Ligandome Analysis Of Chronic Myeloid Leukemia (CML), Revealed Novel Tumor Associated Antigens For Peptide Based Immunotherapy

Juliane S. Stickel, Daniel J. Kowalewski, Mirle Schemionek, Lothar Kanz, MD, Tim H. Brümmendorf, MD, Helmut R. Salih, MD, Hans-Georg Rammensee, Stefan Stevanovic

Blood (2013) 122 (21): 3975.

https://doi.org/10.1182/blood.V122.21.3975.3975

Published: 2013

Journal Articles

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

Elisabeth Bolton-Gillespie, Mirle Schemionek, Hans-Ulrich Klein, Sylwia Flis, Grazyna Hoser, Thoralf Lange, Margaret Nieborowska-Skorska, Jacqueline Maier, Linda Kerstiens, Mateusz Koptyra, Martin C. Müller, Hardik Modi, Tomasz Stoklosa, Ilona Seferynska, Ravi Bhatia, Tessa L. Holyoake, Steffen Koschmieder, Tomasz Skorski

Blood (2013) 121 (20): 4175–4183.

https://doi.org/10.1182/blood-2012-11-466938

Published: 2013

Includes: Supplemental data

Journal Articles

Metastasis Suppressor 1 Is Downregulated in CML Stem Cells and Overexpression Impairs Early Leukemic Cell Propagation.

Mirle Schemionek, PhD, Ulrich Steidl, MD, PhD, Albrecht Schwab, MD, Daniel G Tenen, MD, Copland Mhairi, PhD, Tessa L. Holyoake, PhD, FRCP, FRCPath, Christian Preisinger, PhD, Carsten Mueller-Tidow, MD, Tim H Brümmendorf, Steffen Koschmieder, MD

Blood (2012) 120 (21): 2776.

https://doi.org/10.1182/blood.V120.21.2776.2776

Published: 2012

NARROW

The Unfolded Protein Response Mediates Resistance in AML and Its Therapeutic Targeting Enhances TKI Induced Cell Death in FLT3-ITD + AML

Interplay between PI3K/mTOR Signaling and IRE1a-XBP1 Promotes Survival of Pre-B NRAS G12D all Cells Providing a Therapeutic Vulnerability for the "Undruggable" Driver RAS

The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy

The HLA Ligandome Landscape of Chronic Myeloid Leukemia Delineates Novel T-Cell Epitopes for Immunotherapy

Eosinophil Differentiation and Viability in Hypereosinophilia Is Impaired By Genetic and Pharmacologic Targeting of LCP1 and PKC Beta

Synergistic Dual Inhibition of BCR-ABL1 and the Unfolded Protein Response Causes p38 MAPK-Mediated Cell Death and Sensitizes BCR-ABL1 + Acute Lymphoblastic Leukemia to Dexamethasone

Critical Interferon-Response Genes Are Induced By JAK2 V617F but Repressed By BCR-ABL, and They Are Responsible for the Differential Effects of Interferon in PV Vs. CML

Bcr-Abl1 Kinase-Independent Upregulation of FcγRIIb Mediates Malignant Signaling That Is Critical for Leukemogenesis

Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia Identifies Novel CD8 + and CD4 + T Cell-Epitopes for Immunotherapeutic Approaches

Telomere Length Shortening in the CML Leukemic Stem Cell Compartment Correlates with the Respective Clone Size: Evidence for Early Vs. Late Chronic Phase

Elucidation of Additional Mutations By Next-Generation Sequencing Is of Clinical Significance in Patients with Rare MPNs and MDS/MPN Overlap Syndromes

HLA Ligandome Analysis of Different Hematological Malignancies Identifies a Small Panel of "Pan-Leukemia"-Associated Antigens

Dasatinib Exerts Differential Effects on Normal and BCR-ABL Positive Hematopoietic Cells in a Transgenic Mouse Model of Chronic Phase-CML

A Novel TNF-Alpha Antibody Based Therapeutic Approach to Target Leukemic Stem Cells in Bcr-Abl Disease

Genetic Depletion of Fc Gamma Receptor 2b Affects CML Stem Cell Biology

Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia (CML)—Towards Peptide Based Immunotherapy

Dissecting Genomic Aberrations In CML and Bcr-Abl Negative Myeloproliferative Neoplasms By The Use Of Multiplex-PCR and Parallel Resequencing

HLA Ligandome Analysis Of Chronic Myeloid Leukemia (CML), Revealed Novel Tumor Associated Antigens For Peptide Based Immunotherapy

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

Metastasis Suppressor 1 Is Downregulated in CML Stem Cells and Overexpression Impairs Early Leukemic Cell Propagation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only